Table 1.

Imaging Studies and Their Corresponding Sensitivities and Specificities in Patients Suspected of Cardiac Sarcoid

Authors	Patient Population	Imaging Modality	Sensitivity, %	Specificity, %
Cheong et al, 200920	31 patients with biopsy‐confirmed systemic sarcoidosis	cMRI with gadolinium	NA	NA
Ohira et al, 200821	21 patients with suspected CS by ECG, Holter	cMRI with gadolinium	75	77
Tadamura et al, 200522	10 patients with histologically and clinically diagnosed CS	cMRI with gadolinium	100	NA
Smedema et al, 200524	58 patients with biopsy‐proven pulmonary sarcoid	cMRI with gadolinium	100	58
Smedema et al, 200525	88 patients with biopsy‐proven pulmonary sarcoid	cMRI with gadolinium	100	83
Ohira et al, 200821	21 patients suspected for CS by ECG, Holter	18F‐FDG PET	88	39
Yamagishi et al, 200327	Retrospective study of 17 patients with histologically proven CS	18F‐FDG PET	100	NA
Okumura et al, 200428	22 patients with histologically diagnosed CS	18F‐FDG PET	100	91
Ishimaru et al, 200529	32 patients clinically diagnosed with systemic sarcoid	18F‐FDG PET	100	82
Langah et al, 200930	65 patients with suspected CS	18F‐FDG PET	85	90
		99mTc‐sestamibi6, 30, 31, 39	64–80	93–100
		Gallium‐678, 24, 30, 31, 32	0–36	80–100
		Thallium‐20139	24–58	Insufficient data

Abbreviations: cMRI, cardiac magnetic resonance imaging; CS, cardiac sarcoid; ECG, electrocardiogram; FDG PET, fludeoxyglucose positron‐emission tomography; NA, not applicable.